IDH1 and cholangiocarcinoma: IDH-1 mutation is druggable and its inhibitor, AG-120 (ivosidenib), reduced the risk of progression or death by 63% compared with placebo for pre-treated patients with IDH1-mutant advanced CCA, according to findings from the global, phase 3, multicenter, double-blind, randomized study of AG-120 (ClarIDHy study) [117].